1.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00170, PHII-75, CDR0000492014, N01CM00071, N01CM00038, CCC-PHII-75, 7435, NCI-7435, NCT00365157
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AEZS-108-046, EProst # 20091095, NCT01234519
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SNX-5422-CLN1-008, NCT01848756
|
|
4.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-0933, NCT00756639
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HOG GU10-147, NCT01215136
|
|
6.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOBL204, NCT01215877
|
|
7.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 13943, CP20-0902, I4Y-IE-JCDC, NCT01282463
|
|
8.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: N10-1, NCT01353222
|
|
9.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.392, 2011-52, NCT01437488
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OGX-427-02, NCT01454089
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU10-148, NCT01524991
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-060, NCT01551030
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-071, NCT01589094
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: ERP-GU-052, NCI-2012-00906, IRB#12-015, NCT01611662
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-191, NCT01622660
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2012.038, HUM00062285, NCT01663285
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120205, 12-C-0205, NCT01688999
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU12-160, NCT01780545
|
|
19.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-106, NCT01182168
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02576, UPCI 10-037, U01CA099168, CDR0000693751, PCI-10-037, 8632, NCT01282333
|
|
21.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110140, 11-C-0140, NCT01352962
|
|
22.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02500, UPCI 10-115, CDR0000700997, U01CA069856, U01CA099168, U01CA062502, U01CA070095, U01CA062505, 8808, NCT01366144
|
|
23.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-13419, NCI-2011-0098, NCT01375699
|